Trevena, Inc. (TRVN)
USD 1.27
(-0.78%)
USD 1.27
(-0.78%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 48.26 Million USD | 45.89% |
| 2022 | 33.08 Million USD | 113.49% |
| 2021 | 15.49 Million USD | -34.54% |
| 2020 | 23.67 Million USD | 39.93% |
| 2019 | 16.91 Million USD | -33.01% |
| 2018 | 25.25 Million USD | -33.7% |
| 2017 | 38.08 Million USD | 5.59% |
| 2016 | 36.07 Million USD | 11.95% |
| 2015 | 32.22 Million USD | 252.78% |
| 2014 | 9.13 Million USD | 168.53% |
| 2013 | 3.4 Million USD | -58.15% |
| 2012 | 8.12 Million USD | 103.67% |
| 2011 | 3.99 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 41.9 Million USD | -8.5% |
| 2024 Q1 | 45.79 Million USD | -5.12% |
| 2023 FY | 48.26 Million USD | 45.89% |
| 2023 Q3 | 41.58 Million USD | 43.01% |
| 2023 Q1 | 28.13 Million USD | -14.94% |
| 2023 Q2 | 29.07 Million USD | 3.34% |
| 2023 Q4 | 48.26 Million USD | 16.06% |
| 2022 Q3 | 29.15 Million USD | 1.03% |
| 2022 Q1 | 15.02 Million USD | -3.05% |
| 2022 Q4 | 33.08 Million USD | 13.46% |
| 2022 FY | 33.08 Million USD | 113.49% |
| 2022 Q2 | 28.86 Million USD | 92.12% |
| 2021 FY | 15.49 Million USD | -34.54% |
| 2021 Q4 | 15.49 Million USD | 11.21% |
| 2021 Q1 | 20.42 Million USD | -13.7% |
| 2021 Q3 | 13.93 Million USD | -35.77% |
| 2021 Q2 | 21.69 Million USD | 6.2% |
| 2020 Q3 | 11.35 Million USD | 3.28% |
| 2020 Q1 | 10.25 Million USD | -39.38% |
| 2020 Q2 | 10.99 Million USD | 7.23% |
| 2020 Q4 | 23.67 Million USD | 108.43% |
| 2020 FY | 23.67 Million USD | 39.93% |
| 2019 Q1 | 25.5 Million USD | 0.99% |
| 2019 FY | 16.91 Million USD | -33.01% |
| 2019 Q2 | 22.79 Million USD | -10.63% |
| 2019 Q3 | 22.18 Million USD | -2.65% |
| 2019 Q4 | 16.91 Million USD | -23.76% |
| 2018 Q3 | 27.46 Million USD | -18.33% |
| 2018 FY | 25.25 Million USD | -33.7% |
| 2018 Q4 | 25.25 Million USD | -8.06% |
| 2018 Q2 | 33.63 Million USD | 4.05% |
| 2018 Q1 | 32.32 Million USD | -15.14% |
| 2017 Q2 | 36.4 Million USD | 1.57% |
| 2017 Q1 | 35.84 Million USD | -0.65% |
| 2017 FY | 38.08 Million USD | 5.59% |
| 2017 Q4 | 38.08 Million USD | 1.76% |
| 2017 Q3 | 37.43 Million USD | 2.83% |
| 2016 Q2 | 27.59 Million USD | -2.43% |
| 2016 Q1 | 28.27 Million USD | -12.24% |
| 2016 FY | 36.07 Million USD | 11.95% |
| 2016 Q4 | 36.07 Million USD | 22.53% |
| 2016 Q3 | 29.44 Million USD | 6.71% |
| 2015 Q1 | 16.1 Million USD | 76.31% |
| 2015 FY | 32.22 Million USD | 252.78% |
| 2015 Q4 | 32.22 Million USD | 149.21% |
| 2015 Q3 | 12.92 Million USD | -15.53% |
| 2015 Q2 | 15.3 Million USD | -4.95% |
| 2014 Q4 | 9.13 Million USD | -5.8% |
| 2014 Q3 | 9.69 Million USD | 73.1% |
| 2014 Q1 | 5.3 Million USD | 56.05% |
| 2014 FY | 9.13 Million USD | 168.53% |
| 2014 Q2 | 5.6 Million USD | 5.53% |
| 2013 Q1 | - USD | -100.0% |
| 2013 FY | 3.4 Million USD | -58.15% |
| 2013 Q2 | 3.93 Million USD | 0.0% |
| 2013 Q4 | 3.4 Million USD | -8.88% |
| 2013 Q3 | 3.73 Million USD | -5.13% |
| 2012 FY | 8.12 Million USD | 103.67% |
| 2012 Q4 | 8.12 Million USD | 0.0% |
| 2011 FY | 3.99 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| America Great Health | 4.82 Million USD | -900.256% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -1931.229% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -23.981% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 63.613% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -1636.668% |
| Better Therapeutics, Inc. | 23.84 Million USD | -102.424% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -482.593% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -383.868% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -83.234% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -51.848% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 30.491% |
| Evolutionary Genomics, Inc. | 7.94 Million USD | -507.407% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | -0.314% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 69.324% |
| Innovation1 Biotech Inc. | 3.5 Million USD | -1276.572% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -126.691% |
| Molecular Templates, Inc. | 31.17 Million USD | -54.83% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | -285.636% |
| NexImmune, Inc. | 5.08 Million USD | -849.249% |
| Orgenesis Inc. | 35.53 Million USD | -35.815% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -192.284% |
| Point of Care Nano-Technology, Inc. | 266.41 Thousand USD | -18015.414% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -2002.615% |
| Scopus BioPharma Inc. | 7.45 Million USD | -547.427% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 90.24% |
| Statera Biopharma, Inc. | 22.67 Million USD | -112.829% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -342.203% |
| Vaxxinity, Inc. | 30.94 Million USD | -55.966% |
| Vaccinex, Inc. | 5.94 Million USD | -712.218% |
| Vicapsys Life Sciences, Inc. | 1.96 Million USD | -2351.918% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -25.771% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -1647.637% |